Fibroblast Growth Factor 2—A Predictor of Outcome for Patients Irradiated for Stage II-III Non–Small-Cell Lung Cancer

Rades, Dirk; Setter, Cornelia; Dahl, Olav; Schild, Steven E.; Noack, F.

doi:10.1016/j.ijrobp.2010.08.048

Cited by 17 publications

(11 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lifetime history of tobacco use was the most frequently measured tobacco use history variable (compared to pack years, for example), with 80.1% ( n =105) of studies reporting such data. We found 51.3% (48) to 100.0% (31, 36, 42, 44, 51, 54, 72, 73, 76, 80, 84, 117, 129-132, 135, 145, 147-149) of participants had a positive lifetime history, with nearly half of all relevant studies (47.6%, n =50/105) classifying ≥ 90.0% of participants as current or former smokers.…”

Section: Resultsmentioning

confidence: 79%

“…In 13.7% ( n =18) of papers, the method used to measure tobacco use was unspecified (28, 29, 37, 58, 77, 102, 105, 107, 109, 116, 117, 119, 124, 134, 139, 140, 148, 154). When this information was reported, data were typically collected directly from participants (57.3%, n =75; e.g., (59, 65, 86, 110, 136)).…”

Section: Resultsmentioning

confidence: 99%

“…In 27.5% ( n =36) of studies, there was sufficient information to determine the prevalence of current smoking among participants who were current smokers at cancer diagnosis (4, 5, 34-36, 39, 40, 44, 46, 56, 60, 65, 76, 80-84, 87, 97, 110, 112, 115, 117, 123, 125, 128, 129, 136-138, 142-144, 149, 153). In many cases, the definition used to classify current smokers at cancer diagnosis was unreported (38.9% ( n =14/36) (e.g., (4, 31, 87, 110, 128))).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research

Burris

Studts

DeRosa

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Tobacco use after cancer diagnosis is associated with adverse cancer outcomes, yet reliable prevalence estimates for this behavior are lacking. We conducted a systematic literature review of the prevalence of current tobacco use among individuals with a history of lung or head/neck cancer (CRD #42012002625). An extensive search of electronic databases (MEDLINE, EMBASE, Cochrane Library, CINAHL, PsycINFO, Web of Science) identified 7,777 potentially relevant papers published between 1980 and 2014, and 131 of these yielded pertinent information. Aggregating results across heterogeneous study designs and diverse patient samples, the overall mean prevalence rate of current tobacco use (mostly cigarette smoking) was 33.0% (median=31.0%). Among current tobacco users at cancer diagnosis, the mean prevalence rate of current tobacco use (mostly cigarette smoking) was 53.8% (median=50.3%). In many cases, an operational definition of “current” tobacco use was absent, and biochemical verification of self-reported smoking status was infrequent. These and other observed methodological limitations in the assessment and reporting of cancer patients’ tobacco use underscore the necessity of uniform tobacco use assessment in future clinical research and cancer care.

show abstract

Section: Resultsmentioning

confidence: 79%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research

Burris

Studts

DeRosa

et al. 2015

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…1,[6][7][8] Therefore, the discovery of novel agents or signaling pathway targets that could prevent recurrence after definitive treatment has become increasingly important. [9][10][11][12][13] Preclinical findings have implicated cardiac medications such as angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), which are in wide use as antihypertensive agents, in tumor growth and cancer progression. [14][15][16][17][18] Some clinical investigations indicated that receipt of ACEIs or ARBs was associated with improved outcomes among patients with prostate, hepatocellular, pancreatic, breast, or bladder cancer, [19][20][21][22][23][24] but others have not.…”

Section: Introductionmentioning

confidence: 99%

Incidental Receipt of Cardiac Medications and Survival Outcomes Among Patients With Stage III Non–Small-Cell Lung Cancer After Definitive Radiotherapy

Wang¹,

Liao²,

Zhuang³

et al. 2015

Clinical Lung Cancer

View full text Add to dashboard Cite

“…The most commonly used factor for predicting RT responses is the tumor-node-metastasis (TNM) stage. 5 Weight loss, 6 performance status, 6 and molecular markers 7,8 were reported to predict the outcome and could be used to stratify patients for the most optimal strategy for RT but require further validation. 9 Morphologic changes as reflected by computed tomography (CT) have also been identified as prognostic factors, but technical issues remain (e.g., it is also difficult to differentiate residual tumor from necrosis or fibrosis).…”

mentioning

confidence: 99%

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local Control in Non–Small-Cell Lung Cancer Receiving Radiotherapy: Meta-Analysis

Wang

Liu

et al. 2014

Journal of Thoracic Oncology

138

View full text Add to dashboard Cite

Introduction:The 2-[18F]-Fluorodeoxyglucose (FDG) positron emission tomography (PET/CT) has become an imaging tool for clinical assessment of tumor, node, metastasis in non–small-cell lung cancer (NSCLC). Primary tumor maximum standardized uptake value (SUVmax) on 18F-FDG PET/CT before and after radiation therapy (RT) has been studied as a potential prognostic factor for NSCLC patients receiving radiotherapy. However, the sample sizes of most studies were small, and the results of the prediction value of SUVmax remained undetermined, which lead us to perform a meta-analysis to improve the precision in estimating its effect.Methods:We performed a meta-analysis of published literature for primary tumor SUVmax-based biomarkers of the outcome of NSCLC receiving radiotherapy. The required data for estimation of individual hazard ratios (HRs) to compare patients with a low and a high SUVmax were extracted from each publication. A combined HR was calculated by Stata statistical software (Version 11). All of the results were verified by two persons to ensure its accuracy.Results:Thirteen studies were finally included into this meta-analysis; data are available in 13 studies for pre-RT primary tumor SUVmax and in five studies for post-RT. For overall survival, the combined HR estimate was 1.05 (95% confidence interval [CI], 1.02–1.08) and 1.32 (95% CI, 1.15–1.51) for pre-RT SUVmax and post-RT SUVmax, respectively; 1.26 (95% CI, 1.05–1.52) and 2.01 (95% CI, 1.16–3.46) for local control (LC). In stereotactic body radiotherapy (SBRT) group, HR for LC was 1.11 (95% CI, 1.06–1.18) and 2.19 (95% CI, 1.34–3.60) for pre-SBRT SUVmax and post-SBRT SUVmax, respectively.Conclusion:Both pre-RT and post-RT primary tumor SUVmax can predict the outcome of patients with NSCLC treated with radiotherapy. Patients with high levels of pre-RT SUVmax seemed to have poorer overall survival and LC.

show abstract

Fibroblast Growth Factor 2—A Predictor of Outcome for Patients Irradiated for Stage II-III Non–Small-Cell Lung Cancer

Cited by 17 publications

References 28 publications

Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research

Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research

Incidental Receipt of Cardiac Medications and Survival Outcomes Among Patients With Stage III Non–Small-Cell Lung Cancer After Definitive Radiotherapy

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local Control in Non–Small-Cell Lung Cancer Receiving Radiotherapy: Meta-Analysis

Contact Info

Product

Resources

About